62results about How to "Reduce gastrointestinal side effects" patented technology

A once-a-day oral milnacipran pulsatile release composition has been developed that releases the drug in spaced apart “pulses”. The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. This dosage form provides in vivo drug plasma levels characterized by C_max below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml. The composition provides pulsatile release of milnacipran to produce a therapeutic effect over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.

An oral dosage form for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine, in admixture, in amounts suitable for three times per day administration.

A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.

In accordance with the present invention, it has been unexpectedly found that the administration of an acetylcholinesterase inhibitor in combination with a tricyclic antidepressant having anti-muscarinic properties provides a highly effective and well tolerated treatment for nicotine dependence and dementias, such as Alzheimer's disease (AD). In one aspect, it is effective in the treatment of nicotine dependence, as well as in the treatment and mitigation of nicotine withdrawal symptoms and in the effectuation of smoking cessation. In another aspect, it is effect in the treatment and mitigation of dementias such as Alzheimer's disease.

The invention provides a venlafaxine hydrochloride controlled-release pellet and a preparation method thereof. The venlafaxine hydrochloride controlled-release pellet comprises a blank pellet core, a venlafaxine hydrochloride-containing layer and a controlled-release film, wherein the venlafaxine hydrochloride-containing layer comprises active components including venlafaxine hydrochloride and talcum powder which are in a weight ratio of 12:1-8:1, and the weight ratio of the venlafaxine hydrochloride to the blank pellet core is 4:10-8:10. The venlafaxine hydrochloride controlled-release pellet is prepared by adopting a fluidized bed bottom-spraying venlafaxine hydrochloride applying mode; by using 75 percent alcohol as a solvent, the viscosity of the venlafaxine hydrochloride in a water solution is remarkably lowered, the venlafaxine hydrochloride applying speed is increased; and the prepared venlafaxine hydrochloride containing pellet adopts a bottom-spraying coating process, thus the problem of static electricity generated because of the adoption of the pure organic solvent is overcome; the application process and the wrapping process can be continuously operated in the same device, thus the production efficiency is increased and the production cost is lowered; and no toxic organic solvent is adopted in the whole process, thus the venlafaxine hydrochloride controlled-release pellet is environmental-friendly and is good in stability, and almost no broken pellets or dust is produced.

A showly-releasing roxithromycin contains roxithromycin (30-80 wt.%), slow-releasing assistant (hydroxypropylmethyl cellulose, etc) (10-40 wt.%), and others (hole-forming agent, adhesive, lubricant, etc). Its advantages are long active period (24 hrs.), and low by-effect.

The invention discloses a novel tryptamine derivative. The novel tryptamine derivative is characterized in that the chemical structural formula of the novel tryptamine derivative is as shown in the specification. According to the invention, an intracerebral tryptamine hormone fragment with an anti-neuroinflammation effect and a non-steroidal anti-inflammatory drug salicylic acid and derivatives thereof are subjected to molecular combination; on one hand, COX effect can be inhibited; and on the other hand, the generation of iNOS and inflammatory factors and the activation of immune cells can beinhibited, and the occurrence and development of inflammations are jointly inhibited through multiple mechanisms. Meanwhile, carboxylic acid groups of salicylic acid non-steroidal anti-inflammatory drugs can be removed, so gastrointestinal side effects caused by acidity are reduced. On such a basis, a series of compounds are designed and synthesized; and enzyme inhibition tests, various immune cell tests and animal in-vivo experimental studies prove that the synthesized compounds have good anti-inflammatory and analgesic activity.

Multivitamin/Multimineral supplements are provided for supplementing iron and desirable nutrients in the diet of mammals. The supplements include an iron-amino acid chelate, a form of iron more bioavailable than traditional iron salts. The supplements may further include a pharmaceutically accepted salt form of iron as well as other nutritional vitamins and minerals. The supplements are useful for providing iron for pregnant and lactating females as well as for persons suffering from anemia.

The invention provides wingedtooth laggera herb naphtha extracts with a definite curative effect and clear structure, a method for preparing the wingedtooth laggera herb naphtha extracts, medicinal compositions for treating acute and chronic pharyngitis and application of the wingedtooth laggera herb naphtha extracts or the medicinal compositions. When prepared into a spraying agent, the extracts have the prominent advantage of treating respiratory diseases, and active ingredients can directly reach the affected part, so that the first pass effect is avoided, the bioavailability of the extracts is improved, the dosage of the extracts is reduced, and the adverse reactions caused by the extracts are reduced or eliminated.

The invention discloses tegafur and gimeracil compound injecta, comprising tegafur, gimeracil, one or several kinds of auxiliaries suitable for injecta, and the balance of water for injection, wherein the tegafur and the gimeracil serve as active constituents, and the tegafur and gimeracil compound injecta is characterized in that the molar ratio of tegafur to gimeracil to oteracil potassium is 1:(0.2-0.4):1.

Compositions comprising a guanylyl cyclase C agonist in an amount effective to protect intestinal tissue against radiation or chemotherapy and methods of using such compositions to prevent GI syndrome in cancer patient undergoing radiation or chemotherapy and in individuals exposed to or susceptible to exposure to radiation are disclosed.

he present invention relates to the combination of an alpha-7 nicotinic receptor partial agonist and of an acetylcholinesterase inhibitor. The invention also relates to a pharmaceutical composition comprising the combination according to the invention and to the use thereof in the treatment of cognitive disorders.

Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. This invention also provides methods of reducing CNS and gastrointestinal side effects associated with a long term, dextromethorphan/low-dose quinidine combination therapy.

A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.

The invention discloses tegafur, gimeracil and oteracil potassium compound injecta, comprising tegafur, gimeracil, oteracil potassium, one or several kinds of auxiliaries suitable for injecta, and the balance of water for injection, wherein the tegafur, the gimeracil and the oteracil potassium serve as active constituents, and the tegafur, gimeracil and oteracil potassium compound injecta is characterized in that the molar ratio of tegafur to gimeracil to oteracil potassium is 1:(0.2-0.4):1.

A compound aspirin-tatin medicnie contains proportionally aspirin, the medicine in tatin kind, hypolipemic medicine, dihydroxyaluminium aminoacetate, heavy magnesium carbonate or magnesium aluminate carbonate, skeleton and medical auxiliary. Its application is also disclosed.

The invention provides a biguanide derivative for preventing and treating infarction diseases and application of the biguanide derivative in preparation of a medicine for preventing and treating the infarction diseases. The biguanide derivative has an antiplatelet effect, has an obvious inhibition effect on formation of pulmonary embolism, arterial thrombosis and venous thrombosis, can effectivelyreduce cerebral infarction area and cardiac infarction area, and has an obvious improvement effect on cerebral infarction and myocardial infarction. The effect of the derivative is obviously better than that of a positive control medicine, aspirin. The biguanide derivative can also reduce gastrointestinal side effects and bleeding risks commonly existing in existing clinical antithrombotic drugs.

The present invention relates to a rivastigmine-containing sustained-release pharmaceutical composition and, more specifically, to a rivastigmine-containing sustained-release pharmaceutical composition, which is a sustained-release preparation containing a pH-dependent delayed release phase, wherein, by controlling the release of the pharmaceutical composition to be minimized in the stomach at the initial stage of administration, the pharmaceutical composition can lower the maximum blood concentration (Cmax) compared with existing products while arriving at an effective blood concentration, thereby reducing side effects, and thereafter, maintaining the effective blood concentration through the sustained-release of main ingredients. As a result, the pharmaceutical composition according to the present invention exhibits the same effect as in the existing twice-a-day dosing through only the once-a-day dosing, and can increase the treatment efficiency of patients through the improvement in the convenience of administration of patients.

The invention discloses a benazolin compound preparation for treating cough and a preparation method of the benazolin compound preparation. The compound preparation comprises the following components: benpipralin and cimetidine in a ratio of (0.01-0.03): (0.1-0.3). The raw material medicines in corresponding parts are taken, proper auxiliary materials are added according to corresponding preparation methods of pharmaceutics, and the raw material medicines can be respectively prepared into dosage forms such as tablets, capsules, solutions, syrup, dry suspensions or granules. Benpipralin is a peripheral non-addictive cough relieving medicine and is mainly used for relieving cough caused by various reasons. The cimetidine is a histamine H2 receptor impedance agent, is a hepatodrug enzyme inhibitor, and can inhibit the activity of hepatodrug enzyme and slow down the metabolism of benpipralin, so that the blood concentration of benpipralin is improved, and the curative effect of benpipralin is enhanced; and the cimetidine alleviates the stimulation of the benpipralin to the stomach by inhibiting gastric acid secretion, and reduces the gastrointestinal tract side effect of the benpipralin.